Blood test could predict immunotherapy outcomes for aggressive breast cancer
NCT ID NCT05914961
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for women with triple-negative breast cancer, either early-stage or advanced, who are receiving immunotherapy. Researchers want to see if changes in a simple blood marker called CRP can predict how well the treatment works. The goal is to find a way to personalize therapy and improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC - TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Women's Health
RECRUITINGTübingen, 72076, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Gene-Edited immune cells tame Hard-to-Treat cancers?
- Can a One-Time Anti-Inflammatory shot during surgery curb Triple-Negative breast Cancer's return?
- Triple-Drug cocktail aims to stall aggressive breast cancer
- Could a vaccine stop Triple-Negative breast cancer from coming back?
- Engineered immune cells take aim at Mesothelin-Positive tumors
- New imaging tracer could spot hidden cancers